X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Week in Review: The Latest from PhRMA

By Priscilla VanderVeer  |    May 29, 2015
Meet Tom: Check out our latest patient profile and see how out-of-pocket costs can limit access to needed medicines when it comes to managing HIV/AIDS. How Manufacturing Advances Medicine:...   Read More

Patient Profile: Out-of-Pocket Cost Burden for Patients Treating HIV/AIDS

By Allyson Funk  |    May 28, 2015
Check out our latest patient profile on the challenge of out-of-pocket costs when it comes to managing HIV/AIDS. Our past profiles have explored other chronic conditions like cancer, rheumatoid...   Read More

New Chart Pack: Big Strides in Fight Against Cancer

By John Castellani  |    May 28, 2015
In December 2009, Matt Ellefson received news from his doctor that no one ever wants to receive: a diagnosis of advanced non-small cell lung cancer. He faced a five-year survival rate of less than...   Read More

New White Paper: Recognizing Emerging Value in Oncology Treatments

By Guest Contributor  |    May 27, 2015
Nicole Sweeney is a Manager with Boston Healthcare Associates. She focuses on health policy and market access issues faced by innovators in the pharmaceutical, medical device, and diagnostic space.   Read More

How Manufacturing Advances Can Help Make Medicines More Effective

By Tim McClung  |    May 26, 2015
When we think about innovation in medicine development, we often don’t picture assembly lines or the industrial manufacturing methods that create the tablets, capsules, injectables or I.V....   Read More

Medicare Monday: Happy Memorial Day!

By Allyson Funk  |    May 25, 2015
We wanted to take this #MedicareMonday to wish all of you a happy Memorial Day! But we didn’t want to leave you without some Medicare reading for your day by the pool or grilling on the patio, so...   Read More

Week in Review: The Latest from PhRMA

By Priscilla VanderVeer  |    May 22, 2015
High Out-of-Pocket Costs Hurt Patients: Even with health coverage, approximately 31 million Americans were considered “underinsured” last year due to high deductibles and increasing out-of-pocket...   Read More

Biopharmaceutical Companies Recognized as Meaningful Places to Work

By John Tunnell  |    May 22, 2015
Loretta was diagnosed with Stage 4 lung cancer 12 years ago - but thanks to medical breakthroughs and innovative medicines, she is living a happy, active life today. Matt was given a five percent...   Read More

ICYMI: New Commonwealth Fund Study Shows Health Insurance Does Not Always Translate to Affordable Care

By Allyson Funk  |    May 21, 2015
A new survey from the Commonwealth Fund found nearly a quarter of 19-to-64-year-old Americans with health insurance last year—approximately 31 million people—were considered “underinsured.”...   Read More

340B Spotlight: New Charity Care Data Shows Most Hospitals with Contract Pharmacies Provide Little Charity Care

By Karyn Schwartz  |    May 21, 2015
New data raises even more questions about how hospitals are using for-profit pharmacies to expand a little known program called 340B. This program was designed to allow qualifying hospitals and...   Read More

New Study Illustrates Biopharmaceutical Industry’s Commitment to Personalized Medicine

By Gretta Stone  |    May 20, 2015
Potential personalized medicines represent 42 percent of drugs in the pipeline. This new finding, from a survey by the Tufts Center for the Study for Drug Development (CSDD), is remarkably high,...   Read More

Patents: More Important to Biopharmaceutical Sector than Other Industries

By Setareh Samii  |    May 18, 2015
According to Abraham Lincoln, the patent system “secured to the inventor for a limited time exclusive use of his inventions, and thereby added the fuel of interest to the fire of genius in the...   Read More

Medicare Monday: How Successful Negotiation Takes Place in Medicare

By Allyson Funk  |    May 18, 2015
#MedicareMonday is continuing to take a closer look at proposals that could hurt the success of Medicare Part D. This week we’re talking about proposals to repeal the non-interference clause in...   Read More

WSJ Editorial: SCOTUS Needs to Hear Alameda Case

By Robert Zirkelbach  |    May 18, 2015
A new editorial in the Wall Street Journal, “Bad Drug Trip in Alameda,” highlights a case currently before the Supreme Court (SCOTUS), PhRMA v. Alameda, that challenges a drug take-back program...   Read More

Week in Review: The Latest from PhRMA

By Christian Clymer  |    May 15, 2015
Continued Misconceptions on Cost: This week, another misleading account of spending on medicines was released. The report, issued by Express Scripts, ignored the fact that for the past 50 years,...   Read More

Focusing Payment and Delivery on Patients

By Allyson Funk  |    May 15, 2015
As the way we pay for and deliver health care in the United States evolves, we’ve talked about the importance of patient engagement in the process and ensuring that our system doesn’t treat...   Read More

ICYMI: Next Generation Cures

By Tina Stow  |    May 15, 2015
On Tuesday, May 12th, PhRMA and The Hill convened a symposium with legislators and leading health care experts on “Next Generation Cures.” Speakers and panelists focused on how all health care...   Read More

Ask About Adherence: Q&A with National Consumers League

By Samantha Dougherty  |    May 14, 2015
Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. In this post, we speak with Sally Greenberg, National Consumers League (NCL) executive director, on...   Read More

Yet Another Misleading Report on Medicine Prices

By Robert Zirkelbach  |    May 13, 2015
Today Express Scripts released yet another misleading report to promote a false narrative about medicine spending in the United States.  For more than 50 years, spending on medicines has...   Read More

ICYMI: New Oncology Trend Report Highlights the Future Promise of Innovation

By Lauren Neves  |    May 13, 2015
As part of our Healthy Outlook: Conquering Cancer in the 21st Century blog series, we wanted to highlight a new report from IMS Institute for Healthcare Informatics that examines the global market...   Read More

Voters Agree: Congress Should Protect Patents

By Robert Zirkelbach  |    May 12, 2015
A recent poll by the Morning Consult confirms what is likely intuitive to most: strong intellectual property (IP) rights are important to voters for a variety of reasons. In the recent poll, a...   Read More

Medicare Monday: Why Medicaid-Style Rebates Aren’t Good for Part D Beneficiaries or the Program

By Allyson Funk  |    May 11, 2015
This week in the #MedicareMonday series we’re taking a closer look at proposals that could hurt the success of Medicare Part D. One such proposal is to apply mandatory Medicaid-style rebates to...   Read More

RIYB Event in Pennsylvania Spreads Awareness of Clinical Trials

By Priscilla VanderVeer  |    May 8, 2015
To kick off the start of National Clinical Trials Awareness Week, on Monday, May 4, We Work For Health Pennsylvania hosted a Research in Your Backyard (RIYB) roundtable discussion with Congressman...   Read More

Loretta Shares a Story of Hope in the Face of Her Cancer Diagnosis

By Holly Campbell  |    May 7, 2015
When Loretta was diagnosed with Stage IV lung cancer in February 2003, she thought it was a death sentence. The news came as a shock to her and her family; she had two young children to care for...   Read More

What They Aren’t Telling You About Medicine Prices

By Holly Campbell  |    May 6, 2015
Recent cries from Bloomberg and The New York Times of “skyrocketing” medicine prices make for great headlines.  But what’s not being talked about is that these claims are based solely on the list...   Read More

India’s IP Policies: Still Much Room for Improvement

By Mark Grayson  |    May 6, 2015
PhRMA Associate Vice President Amiee Aloi testified on May 5 before a U.S. International Trade Commission hearing examining the progress India is making to address relevant industrial trade and...   Read More

World Asthma Day: New Hope for Millions with Asthma

By Christian Clymer  |    May 5, 2015
While the 5th of May is most often thought of as Cinco de Mayo, the first Tuesday in May also marks another important day of awareness: World Asthma Day. For more than 24 million Americans living...   Read More

ICYMI: The New York Times Highlights How Increasing Cost Sharing Hinders Access, Raises Other Health Care Costs

By Allyson Funk  |    May 5, 2015
Yesterday, on The Upshot, Incidental Economist creator Austin Frakt explored the impact of high cost-sharing on consumers and other health care costs. He reiterates concerns we’ve been...   Read More

New Law Overrules State Supreme Court’s “Innovator Liability” Decision

By Guest Contributor  |    May 4, 2015
On Friday, May 1, Alabama Governor Robert Bentley signed into law legislation that overturns the Alabama Supreme Court’s adoption of a novel tort theory that severely threatened Alabama’s...   Read More

Celebrating Clinical Trials Awareness Week: May 4-8

By Jocelyn Ulrich  |    May 4, 2015
Chances are very good that you or a loved one recently reached into your cabinet to take a medicine to treat a condition, prevent a disease or alleviate a symptom. But when was the last time you...   Read More

Medicare Monday: Tampering with the Successful Structure of Part D

By Allyson Funk  |    May 4, 2015
First, in case you missed it, last week CMS released new Part D utilization and cost data for 2013. While we support efforts to increase transparency, this data release is very misleading and...   Read More

Costs and Consequences of Not Treating Diabetes

By Holly Campbell  |    May 1, 2015
  Costs and Consequences is a blog series examining the health care burden of not treating diseases. Too often, the rhetoric focuses solely on the cost of medicines and disregards the adverse...   Read More

5 Things to Know About the CMS Part D Data Release

By Allyson Funk  |    May 1, 2015
1. Part D’s competitive, market-based structure is unique among government programs. As required by law, Part D is different than other parts of Medicare and other government programs because it...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates